about
Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesionsProteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinomaHuman Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical CarcinomasFrequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumorsGenetic characterization of large parathyroid adenomasProlactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated geneParathyroid carcinoma arising from four-gland hyperplasia.Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism.Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma.A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.HRAS mutation prevalence and associated expression patterns in pheochromocytoma.Minimally invasive follicular thyroid carcinomas: prognostic factorsGenetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.Diffuse parathyroid hormone expression in parathyroid tumors argues against important functional tumor subclones.Inflammatory Infiltrates in Parathyroid Tumors.Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma.Evidence of a functional estrogen receptor in parathyroid adenomas.Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B pathway in human testicular germ cell tumors.Long-term storage of endocrine tissues at - 80°C does not adversely affect RNA quality or overall histomorphologyThe VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma.TERT promoter mutations are rare in parathyroid tumors.Transcriptional profiling enables molecular classification of adrenocortical tumours.Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma.Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.Absence of KMT2D/MLL2 mutations in abdominal paraganglioma.Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.Detailed Lymph Node Sectioning of Papillary Thyroid Carcinoma Specimen Increases the Number of pN1a Patients.Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma.Absence of the BRAF V600E mutation in pheochromocytoma.Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman - a case report.Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report
P50
Q21090550-34440364-C1C1-462C-95A1-D637DB117062Q28287879-47CE543C-E97B-483B-A217-466CB5A17F98Q28553895-E24B2F05-54FA-4D15-AA4F-692079B3033BQ30979173-8203C705-8297-4CE2-B900-7A6AC216E7BAQ33570215-02298903-E4F7-4E56-8733-A49B51CA8390Q33709979-1A5FEA60-EDA6-43F6-A3EE-9EB6A9270771Q34264055-4BBEF189-0501-499F-A47E-8CE8204CF10AQ34273584-2F28612C-5DB1-45A3-AAD2-EC992D4FBF2EQ34431091-473790DC-3307-42E8-AFF0-320438FD1094Q34478820-B0E00AF5-B937-4571-88EB-71724461938DQ34792877-B1751568-0E18-4384-B315-3DE3D56EB161Q35153386-1BD117B6-2C4F-4FF1-9CF8-D2613D8C1610Q35234108-37A75429-074F-429A-8057-B698BAE91F5EQ35534007-74496694-4C58-45BC-911F-ED808AF5A98BQ36107501-26671089-CA2F-481C-9CBE-BC505BC3E72DQ36294469-A0E97FA4-FA51-4134-B0EA-79B8589BCBE3Q36694372-68FE27AB-28AE-42E1-A2F2-E858FF773E1FQ37104637-B5D15810-EC24-46EE-BF62-C9CB8B6BF2EEQ37225274-FC2DCEA2-05B5-441A-A591-1390E6A17FF9Q37369600-CF870929-17DD-4257-BBAF-C74916F8A21BQ38372011-093C4825-4B9F-4C46-A473-AB0B2C12F051Q38722070-AA6277A4-21BC-4134-8693-A3FC3D63E3BAQ39268677-739EBF1B-ADAE-4752-9E44-61F3CA87129BQ41082340-D02254AB-7D1B-47B3-8E21-18D1C0679455Q41891080-5D73BCB1-CEB6-4E79-B745-7C1A89AD9957Q41975304-CDA67A75-08B7-490E-8E22-D6C09E1371FDQ43481604-88B5F1EC-8C38-424D-AD9E-B103D7729B63Q45237414-F6359982-228C-4C1B-82AA-24B21166B860Q46027535-624E999E-D961-404E-9A24-62445DA9DB1BQ48318640-42612D4F-4C48-41E4-8D14-D16F4ADBE273Q50692553-57CF53C4-C2A5-4745-95A9-CD524E31AD42Q52150621-E11FBB4D-ED07-4650-9505-1C6BC7400AECQ52606764-7D4CBC34-AF2F-446B-B6AE-5C9F377F6E68Q53088180-0541673C-43BA-42E6-8AC8-9F91E9167C5EQ53316851-C7C79E0D-231B-4FB4-8FC6-6348E11CE939Q54225773-5DC0FD5B-E59B-4F3C-BFBC-54274EAF2197Q54321528-67213FBE-7FF5-4A0C-B599-E9F1517DCB7DQ54347306-B47B02B7-B380-4E35-8DD8-04E4FC48F1EEQ55664943-28D0688A-C519-4408-8E2A-8A608F2E2EA0Q58103587-2DDEF39B-2A1D-4C7A-A784-2618B5B81AE0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carl C Juhlin
@ast
Carl C Juhlin
@en
Carl C Juhlin
@es
Carl C Juhlin
@nl
Carl C Juhlin
@sl
type
label
Carl C Juhlin
@ast
Carl C Juhlin
@en
Carl C Juhlin
@es
Carl C Juhlin
@nl
Carl C Juhlin
@sl
prefLabel
Carl C Juhlin
@ast
Carl C Juhlin
@en
Carl C Juhlin
@es
Carl C Juhlin
@nl
Carl C Juhlin
@sl
P106
P21
P31
P496
0000-0002-5945-9081